D-0824-2021 Class II Terminated

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0824-2021 was initiated by Glenmark Pharmaceuticals Inc., USA on Aug 27, 2021 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Oct 4, 2023). Affected quantity: 4752 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 29, 2021
Initiation Date
Aug 27, 2021
Termination Date
Oct 4, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4752 bottles

Product description

Chlorzoxazone Tablets USP 750 mg 100 Tablets Rx Only NDC 68462-725-01 Manufactured by: Glenmark Pharmaceuticals Inc., USA 4147 Goldmine Road Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide.

Code information

Lots: 29200023 Exp. 03/31/2022; 29200025 Exp. 03/31/2022; 29200036 Exp. 06/30/2022; 29200056 Exp. 09/30/2022; 29200070 Exp. 11/30/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0824-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0824-2021. Report a data issue: hello@regdatalab.com.